Release date: 2017-03-29 IBM recently launched its first cognitive imaging product, the IBM Watson Imaging Clinical Review, and announced the expansion of the Watson Health Medical Imaging Partnership to 24 organizations worldwide for the treatment of eye, brain, chest, heart and related conditions. The global program adds industry experts and clinical experience. Source: China Netcom Xeroform Gauze,Xeroform Dressing,Xeroform Bandage,Xeroform Gauze Walgreens Roosin Medical Co.,Ltd , https://www.roosinmedical.com
The first cognitive imaging product release can alert the doctors of the dangers that are not visible to doctors.
IBM is imagining the future of artificial intelligence + healthcare for thousands of medical IT professionals, clinicians, corporate executives and industry chain supplier representatives, proclaiming cognitive computing as a golden age for personalized medicine and precision medicine.
First cognitive imaging product
The main roles of the IBM Watson Imaging Clinical Review are:
Medical data, including images, can be examined to alert medical workers in critical situations.
The cognitive text analysis reads the structured and unstructured information in the cardiologist's medical records, and combines with other sources to verify the accuracy of key data (including diagnostic results) in the medical records.
The hospital administrator can identify the condition that should be followed up for treatment and ensure that it is recorded in the medical record.
The Watson Health Medical Imaging Partnership is comprised of leading health systems, academic medical centers, private radiology practice organizations, mobile radiology service providers and imaging technology companies looking for ways to identify and predict possible cancers in medical imaging technology. Risk of diabetes, eye, brain and heart disease and related patients.
IBM's cognitive imaging products examine medical data, including images, to help healthcare providers identify the most critical situations that need attention.
The first application target for this product is cardiovascular disease, which begins with a common condition called AS for aortic stenosis. In the United States, AS affects 1.5 million people. A pilot study found that cognitive computing systems can help medical staff identify potential AS patients who have not previously indicated their need for follow-up care for coronary heart disease.
With this system, hospital administrators can identify conditions with follow-up treatment. It uses cognitive text analysis to read structured and unstructured information from cardiologist medical reports, combine it with various data from other sources, and extract relevant information to validate key data (including diagnostic results). Whether it is accurately reflected in the health record.
“The Watson Cognitive Imaging product is an AI-driven, targeted tool that providers can use to standardize the implementation of treatment across the organization and gradually build a large number of vitally repeatable results through their patient population. It can help organizations achieve a personalized approach to population health," said a medical imaging and informatics analyst.